We agree with the observation of Wang et al about the hyperplasia of tunica media of the umbilical artery suggesting evidence of "fetal hypertension." 1 As Wang et al mention, 1 neonates with fetal hypertension need careful evaluation at birth and subsequent follow-up to detect neonatal and pediatric hypertension.
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Hypertension in pregnancy is associated with considerable adverse outcomes for both fetuses and mothers, such as preterm birth, preeclampsia, and intrauterine growth restriction. 2 Furthermore, women who experience pregnancy-induced hypertension are at increased risk for future cardiovascular disease (eg, hypertension, left ventricular hypertrophy/dysfunction, vascular and renal dysfunction). 2 Besides the effects mentioned by Wang et al, 1 hypertension during pregnancy has an effect on bone mineral density and maternal bone turnover. 3, 4 Certain adipocytokines, namely leptin, adiponectin, resistin, visfatin, and apelin modulate maternal energy metabolism and are differentially regulated in pregnancy complications, including pregnancy-induced hypertension and preeclampsia. 5 We previously demonstrated that in pregnancies complicated with gestational hypertension, maternal concentrations of apelin negatively correlate with crosslinked N-telopeptide of type I collagen (r ¼ -.489; P ¼ .034), a circulating marker of bone resorption. 6 In addition, maternal visfatin concentrations positively correlate with circulating osteoprotegerin levels (r ¼ .464; P ¼ .039), another biomarker of bone resorption. 6 These findings indicate that both apelin and visfatin are implicated in bone metabolism in pregnancies complicated by preeclampsia and pregnancyinduced hypertension. 6 Circulating maternal apelin and visfatin levels may therefore serve as biomarkers of maternal bone turnover and bone mineral density in pregnancy-induced hypertension and preeclampsia.
Current evidence suggests that hypertension in pregnancy is associated with adverse outcomes not only for the fetuses 1 but also for the mothers. [2] [3] [4] [5] [6] Primary prevention strategies should aim at reducing the incidence of pregnancy-induced hypertension to optimize outcomes for both mothers and fetuses. Future studies should elucidate the role of several biomarkers (eg, apelin, 6 visfatin, 6 endocan, 7-10 C-reactive protein, 11 etc) as potential prognostic indicators for the development of future cardiovascular disease in women with pregnancy-induced hypertension.
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